Ophthalmology Management
@ophthalmologymg.bsky.social
Okyo reports favorable corneal nerve data in phase 2 study
Patients treated with 0.05% urcosimod demonstrated a positive reduction in neuropathic corneal pain, & favorable changes in corneal nerve structure that were not observed in the placebo group.
🔗 https://ow.ly/oTNG50XN4SA
#Ophthalmology
Patients treated with 0.05% urcosimod demonstrated a positive reduction in neuropathic corneal pain, & favorable changes in corneal nerve structure that were not observed in the placebo group.
🔗 https://ow.ly/oTNG50XN4SA
#Ophthalmology
December 26, 2025 at 4:05 PM
Okyo reports favorable corneal nerve data in phase 2 study
Patients treated with 0.05% urcosimod demonstrated a positive reduction in neuropathic corneal pain, & favorable changes in corneal nerve structure that were not observed in the placebo group.
🔗 https://ow.ly/oTNG50XN4SA
#Ophthalmology
Patients treated with 0.05% urcosimod demonstrated a positive reduction in neuropathic corneal pain, & favorable changes in corneal nerve structure that were not observed in the placebo group.
🔗 https://ow.ly/oTNG50XN4SA
#Ophthalmology
👁️ Presbyopia drops are more than just a treatment, they’re a gateway to lifelong eye care.
Mitchell Jackson & Melissa Bollinger discuss how these drops serve as a strategic entry point, offering flexibility, discretion, and personalized care to patients. 🌟
🔗 https://ow.ly/aLqM50XKavS
#Presbyopia
Mitchell Jackson & Melissa Bollinger discuss how these drops serve as a strategic entry point, offering flexibility, discretion, and personalized care to patients. 🌟
🔗 https://ow.ly/aLqM50XKavS
#Presbyopia
December 23, 2025 at 1:20 PM
👁️ Presbyopia drops are more than just a treatment, they’re a gateway to lifelong eye care.
Mitchell Jackson & Melissa Bollinger discuss how these drops serve as a strategic entry point, offering flexibility, discretion, and personalized care to patients. 🌟
🔗 https://ow.ly/aLqM50XKavS
#Presbyopia
Mitchell Jackson & Melissa Bollinger discuss how these drops serve as a strategic entry point, offering flexibility, discretion, and personalized care to patients. 🌟
🔗 https://ow.ly/aLqM50XKavS
#Presbyopia
👁️ Laser “top-up” may help keep glaucoma pressure down 👇
A study found MicroPulse transscleral laser retreatment can safely & effectively further lower eye pressure in moderate–advanced glaucoma. At 3 months, IOP dropped ~25–35%.
👉 Read more: https://ow.ly/9CSr50XKpRZ
#Glaucoma
A study found MicroPulse transscleral laser retreatment can safely & effectively further lower eye pressure in moderate–advanced glaucoma. At 3 months, IOP dropped ~25–35%.
👉 Read more: https://ow.ly/9CSr50XKpRZ
#Glaucoma
December 18, 2025 at 1:20 AM
👁️ Laser “top-up” may help keep glaucoma pressure down 👇
A study found MicroPulse transscleral laser retreatment can safely & effectively further lower eye pressure in moderate–advanced glaucoma. At 3 months, IOP dropped ~25–35%.
👉 Read more: https://ow.ly/9CSr50XKpRZ
#Glaucoma
A study found MicroPulse transscleral laser retreatment can safely & effectively further lower eye pressure in moderate–advanced glaucoma. At 3 months, IOP dropped ~25–35%.
👉 Read more: https://ow.ly/9CSr50XKpRZ
#Glaucoma
🟢 FDA approved Alembic’s generic version of Zylet - a combo eye drop with a steroid + antibiotic. Alembic says it may get 180 days of “first-generic” exclusivity after launch.
Read more: https://ow.ly/KBEn50XKpzn
#FDA #Generics #EyeHealth #Ophthalmology
Read more: https://ow.ly/KBEn50XKpzn
#FDA #Generics #EyeHealth #Ophthalmology
December 17, 2025 at 4:15 AM
🟢 FDA approved Alembic’s generic version of Zylet - a combo eye drop with a steroid + antibiotic. Alembic says it may get 180 days of “first-generic” exclusivity after launch.
Read more: https://ow.ly/KBEn50XKpzn
#FDA #Generics #EyeHealth #Ophthalmology
Read more: https://ow.ly/KBEn50XKpzn
#FDA #Generics #EyeHealth #Ophthalmology
👁️ Corneal scarring can reduce vision - but transplant isn’t always the answer.
Sumitra S. Khandelwal, MD shares a stepwise approach: medical therapy first, scleral lenses to rehab vision, then depth-based surgery, with PKP reserved for severe cases.
🔗 https://ow.ly/5aQf50XJIKW
#Ophthalmology
Sumitra S. Khandelwal, MD shares a stepwise approach: medical therapy first, scleral lenses to rehab vision, then depth-based surgery, with PKP reserved for severe cases.
🔗 https://ow.ly/5aQf50XJIKW
#Ophthalmology
December 16, 2025 at 3:01 PM
👁️ Corneal scarring can reduce vision - but transplant isn’t always the answer.
Sumitra S. Khandelwal, MD shares a stepwise approach: medical therapy first, scleral lenses to rehab vision, then depth-based surgery, with PKP reserved for severe cases.
🔗 https://ow.ly/5aQf50XJIKW
#Ophthalmology
Sumitra S. Khandelwal, MD shares a stepwise approach: medical therapy first, scleral lenses to rehab vision, then depth-based surgery, with PKP reserved for severe cases.
🔗 https://ow.ly/5aQf50XJIKW
#Ophthalmology
👓 Presbyopia is unavoidable - but patients want solutions earlier than ever.
Here, Kathryn M. Hatch, MD breaks down today’s surgical + nonsurgical options (RLE, advanced IOLs, monovision, drops) and why patient selection & expectation-setting matter as much as the tech.
🔗 https://ow.ly/QfrF50XJIae
Here, Kathryn M. Hatch, MD breaks down today’s surgical + nonsurgical options (RLE, advanced IOLs, monovision, drops) and why patient selection & expectation-setting matter as much as the tech.
🔗 https://ow.ly/QfrF50XJIae
December 15, 2025 at 4:50 PM
👓 Presbyopia is unavoidable - but patients want solutions earlier than ever.
Here, Kathryn M. Hatch, MD breaks down today’s surgical + nonsurgical options (RLE, advanced IOLs, monovision, drops) and why patient selection & expectation-setting matter as much as the tech.
🔗 https://ow.ly/QfrF50XJIae
Here, Kathryn M. Hatch, MD breaks down today’s surgical + nonsurgical options (RLE, advanced IOLs, monovision, drops) and why patient selection & expectation-setting matter as much as the tech.
🔗 https://ow.ly/QfrF50XJIae
👁️ Dry eye drug update
Following a positive FDA pre-NDA meeting for AZR-MD-001, Azura Ophthalmics Ltd. says it plans NDA submission with completed efficacy studies.
👉 Read the full update: https://ow.ly/a2Ck50XImG3
#DryEye #MGD #Ophthalmology
Following a positive FDA pre-NDA meeting for AZR-MD-001, Azura Ophthalmics Ltd. says it plans NDA submission with completed efficacy studies.
👉 Read the full update: https://ow.ly/a2Ck50XImG3
#DryEye #MGD #Ophthalmology
December 12, 2025 at 2:02 PM
👁️ Dry eye drug update
Following a positive FDA pre-NDA meeting for AZR-MD-001, Azura Ophthalmics Ltd. says it plans NDA submission with completed efficacy studies.
👉 Read the full update: https://ow.ly/a2Ck50XImG3
#DryEye #MGD #Ophthalmology
Following a positive FDA pre-NDA meeting for AZR-MD-001, Azura Ophthalmics Ltd. says it plans NDA submission with completed efficacy studies.
👉 Read the full update: https://ow.ly/a2Ck50XImG3
#DryEye #MGD #Ophthalmology
Presbyopia drops are becoming a front-door conversation, not an afterthought. 💧
In this video, Mitchell Jackson, MD, and Melissa Bollinger, OD share who they offer drops to first and how it can build long-term patient relationships.
Watch now: https://ow.ly/W7sw50XFKk4
#Ophthalmology
In this video, Mitchell Jackson, MD, and Melissa Bollinger, OD share who they offer drops to first and how it can build long-term patient relationships.
Watch now: https://ow.ly/W7sw50XFKk4
#Ophthalmology
December 10, 2025 at 4:40 PM
Presbyopia drops are becoming a front-door conversation, not an afterthought. 💧
In this video, Mitchell Jackson, MD, and Melissa Bollinger, OD share who they offer drops to first and how it can build long-term patient relationships.
Watch now: https://ow.ly/W7sw50XFKk4
#Ophthalmology
In this video, Mitchell Jackson, MD, and Melissa Bollinger, OD share who they offer drops to first and how it can build long-term patient relationships.
Watch now: https://ow.ly/W7sw50XFKk4
#Ophthalmology
🚨 Cornea update: EyeYon Medical has FDA IDE approval to launch a US clinical study of EndoArt, a synthetic endothelial layer for chronic corneal edema.
The study will be led by Professor Francis Mah, MD.
Read the full update: https://ow.ly/31Wl50XG8sg
#Cornea #Ophthalmology
The study will be led by Professor Francis Mah, MD.
Read the full update: https://ow.ly/31Wl50XG8sg
#Cornea #Ophthalmology
December 9, 2025 at 10:25 AM
🚨 Cornea update: EyeYon Medical has FDA IDE approval to launch a US clinical study of EndoArt, a synthetic endothelial layer for chronic corneal edema.
The study will be led by Professor Francis Mah, MD.
Read the full update: https://ow.ly/31Wl50XG8sg
#Cornea #Ophthalmology
The study will be led by Professor Francis Mah, MD.
Read the full update: https://ow.ly/31Wl50XG8sg
#Cornea #Ophthalmology
Compounded imiquimod for diffuse conjunctival MIS/OSSN? 👁️🧴
A Northwestern case series reports 80% complete histologic response, but every patient had side effects. Could this fill a treatment gap when standard options are tough?
Read on: https://ow.ly/w62I50XCCFE
#Ophthalmology #EyeCancer
A Northwestern case series reports 80% complete histologic response, but every patient had side effects. Could this fill a treatment gap when standard options are tough?
Read on: https://ow.ly/w62I50XCCFE
#Ophthalmology #EyeCancer
December 8, 2025 at 3:20 PM
Compounded imiquimod for diffuse conjunctival MIS/OSSN? 👁️🧴
A Northwestern case series reports 80% complete histologic response, but every patient had side effects. Could this fill a treatment gap when standard options are tough?
Read on: https://ow.ly/w62I50XCCFE
#Ophthalmology #EyeCancer
A Northwestern case series reports 80% complete histologic response, but every patient had side effects. Could this fill a treatment gap when standard options are tough?
Read on: https://ow.ly/w62I50XCCFE
#Ophthalmology #EyeCancer
Can a 5-year visit help predict long-term outcomes in childhood glaucoma? 👁️🧒
A new study found key early measures, especially at year 5, were linked to long-term visual acuity and IOP, and calls for better severity staging to guide care.
Read more: https://ow.ly/6wht50XCCwn
#Ophthalmology#Glaucoma
A new study found key early measures, especially at year 5, were linked to long-term visual acuity and IOP, and calls for better severity staging to guide care.
Read more: https://ow.ly/6wht50XCCwn
#Ophthalmology#Glaucoma
December 5, 2025 at 2:15 PM
Can a 5-year visit help predict long-term outcomes in childhood glaucoma? 👁️🧒
A new study found key early measures, especially at year 5, were linked to long-term visual acuity and IOP, and calls for better severity staging to guide care.
Read more: https://ow.ly/6wht50XCCwn
#Ophthalmology#Glaucoma
A new study found key early measures, especially at year 5, were linked to long-term visual acuity and IOP, and calls for better severity staging to guide care.
Read more: https://ow.ly/6wht50XCCwn
#Ophthalmology#Glaucoma
Precise Bio has achieved the world’s first successful 3D-bio-printed corneal implant.
A legally blind patient in Israel received the PB-001 implant, marking a major step toward lab-grown, donor-free corneal tissue. Early trial results expected in 2026. 👁️🧬
Read more: https://ow.ly/Cu2050XybxT
A legally blind patient in Israel received the PB-001 implant, marking a major step toward lab-grown, donor-free corneal tissue. Early trial results expected in 2026. 👁️🧬
Read more: https://ow.ly/Cu2050XybxT
December 4, 2025 at 4:30 PM
Precise Bio has achieved the world’s first successful 3D-bio-printed corneal implant.
A legally blind patient in Israel received the PB-001 implant, marking a major step toward lab-grown, donor-free corneal tissue. Early trial results expected in 2026. 👁️🧬
Read more: https://ow.ly/Cu2050XybxT
A legally blind patient in Israel received the PB-001 implant, marking a major step toward lab-grown, donor-free corneal tissue. Early trial results expected in 2026. 👁️🧬
Read more: https://ow.ly/Cu2050XybxT
New option for dry eye care 👁️💧
The FDA has approved Amneal’s cyclosporine ophthalmic emulsion 0.05%, a preservative-free formulation in single-use vials and the generic equivalent of Restasis.
Read more 🔗 https://ow.ly/2CWu50XBhGQ
#Ophthalmology #DryEye
The FDA has approved Amneal’s cyclosporine ophthalmic emulsion 0.05%, a preservative-free formulation in single-use vials and the generic equivalent of Restasis.
Read more 🔗 https://ow.ly/2CWu50XBhGQ
#Ophthalmology #DryEye
December 3, 2025 at 2:50 PM
New option for dry eye care 👁️💧
The FDA has approved Amneal’s cyclosporine ophthalmic emulsion 0.05%, a preservative-free formulation in single-use vials and the generic equivalent of Restasis.
Read more 🔗 https://ow.ly/2CWu50XBhGQ
#Ophthalmology #DryEye
The FDA has approved Amneal’s cyclosporine ophthalmic emulsion 0.05%, a preservative-free formulation in single-use vials and the generic equivalent of Restasis.
Read more 🔗 https://ow.ly/2CWu50XBhGQ
#Ophthalmology #DryEye
👁️ New in the US: Evoq Technologies has received FDA registration for Twilight (Class I). It’s designed to help screen for signs of AMD, diabetic eye disease, and inherited retinal disease without a dark room, dilation, or disrupting clinic flow.
Read more: https://ow.ly/FmHO50XAveR
#EyeHealth #AMD
Read more: https://ow.ly/FmHO50XAveR
#EyeHealth #AMD
December 2, 2025 at 2:25 PM
👁️ New in the US: Evoq Technologies has received FDA registration for Twilight (Class I). It’s designed to help screen for signs of AMD, diabetic eye disease, and inherited retinal disease without a dark room, dilation, or disrupting clinic flow.
Read more: https://ow.ly/FmHO50XAveR
#EyeHealth #AMD
Read more: https://ow.ly/FmHO50XAveR
#EyeHealth #AMD
Big news for ophthalmic ASCs 👁️📈
CMS has finalized its 2026 payment rule with a 2.6% increase to ASC reimbursement and higher-than-expected rates for cataract surgery after strong advocacy from ophthalmology groups.
Read more: https://ow.ly/muCY50Xy7P8
#Ophthalmology
CMS has finalized its 2026 payment rule with a 2.6% increase to ASC reimbursement and higher-than-expected rates for cataract surgery after strong advocacy from ophthalmology groups.
Read more: https://ow.ly/muCY50Xy7P8
#Ophthalmology
December 1, 2025 at 2:45 PM
Big news for ophthalmic ASCs 👁️📈
CMS has finalized its 2026 payment rule with a 2.6% increase to ASC reimbursement and higher-than-expected rates for cataract surgery after strong advocacy from ophthalmology groups.
Read more: https://ow.ly/muCY50Xy7P8
#Ophthalmology
CMS has finalized its 2026 payment rule with a 2.6% increase to ASC reimbursement and higher-than-expected rates for cataract surgery after strong advocacy from ophthalmology groups.
Read more: https://ow.ly/muCY50Xy7P8
#Ophthalmology
Payment cuts, parity decisions, and new compliance rules are coming for ophthalmic ASCs.
At #AAO2025, Mike Romansky, JD, broke down what centers need to prepare for — including a 4.7% cataract rate drop and new PA requirements.
Full recap:
https://ow.ly/N3eV50Xuy17
#Ophthalmology
At #AAO2025, Mike Romansky, JD, broke down what centers need to prepare for — including a 4.7% cataract rate drop and new PA requirements.
Full recap:
https://ow.ly/N3eV50Xuy17
#Ophthalmology
November 26, 2025 at 3:50 PM
Payment cuts, parity decisions, and new compliance rules are coming for ophthalmic ASCs.
At #AAO2025, Mike Romansky, JD, broke down what centers need to prepare for — including a 4.7% cataract rate drop and new PA requirements.
Full recap:
https://ow.ly/N3eV50Xuy17
#Ophthalmology
At #AAO2025, Mike Romansky, JD, broke down what centers need to prepare for — including a 4.7% cataract rate drop and new PA requirements.
Full recap:
https://ow.ly/N3eV50Xuy17
#Ophthalmology
CMS has delayed the ASC prior authorization program to early 2026, following advocacy from OOSS, AAO & others.
The PA rollout—affecting blepharoplasty, ptosis repair, brow lifts & Botox in 10 states—was set for Dec 15.
Read more → https://ow.ly/GYL250XwKEK
#Ophthalmology #ASC
The PA rollout—affecting blepharoplasty, ptosis repair, brow lifts & Botox in 10 states—was set for Dec 15.
Read more → https://ow.ly/GYL250XwKEK
#Ophthalmology #ASC
November 25, 2025 at 1:30 PM
CMS has delayed the ASC prior authorization program to early 2026, following advocacy from OOSS, AAO & others.
The PA rollout—affecting blepharoplasty, ptosis repair, brow lifts & Botox in 10 states—was set for Dec 15.
Read more → https://ow.ly/GYL250XwKEK
#Ophthalmology #ASC
The PA rollout—affecting blepharoplasty, ptosis repair, brow lifts & Botox in 10 states—was set for Dec 15.
Read more → https://ow.ly/GYL250XwKEK
#Ophthalmology #ASC
📢 Sydnexis has announced that the FDA has issued a Complete Response Letter for its NDA for SYD-101, a proprietary 0.01% atropine formulation intended to slow myopia progression in children.
Full article: https://ow.ly/W3A850XwTK0
#Ophthalmology #OphthalmologyNews #MyopiaControl
Full article: https://ow.ly/W3A850XwTK0
#Ophthalmology #OphthalmologyNews #MyopiaControl
November 24, 2025 at 3:25 PM
📢 Sydnexis has announced that the FDA has issued a Complete Response Letter for its NDA for SYD-101, a proprietary 0.01% atropine formulation intended to slow myopia progression in children.
Full article: https://ow.ly/W3A850XwTK0
#Ophthalmology #OphthalmologyNews #MyopiaControl
Full article: https://ow.ly/W3A850XwTK0
#Ophthalmology #OphthalmologyNews #MyopiaControl
📉✨ New long-term GA data is in.
Apellis reports that 5 years of continuous Syfovre treatment slowed lesion growth by ~1.5 years vs projected sham — with consistent safety through year 5.
Full story: https://ow.ly/ZOpo50Xuz76
#Ophthalmology #Retina #GA #AMD #ClinicalTrials
Apellis reports that 5 years of continuous Syfovre treatment slowed lesion growth by ~1.5 years vs projected sham — with consistent safety through year 5.
Full story: https://ow.ly/ZOpo50Xuz76
#Ophthalmology #Retina #GA #AMD #ClinicalTrials
November 24, 2025 at 2:25 PM
📉✨ New long-term GA data is in.
Apellis reports that 5 years of continuous Syfovre treatment slowed lesion growth by ~1.5 years vs projected sham — with consistent safety through year 5.
Full story: https://ow.ly/ZOpo50Xuz76
#Ophthalmology #Retina #GA #AMD #ClinicalTrials
Apellis reports that 5 years of continuous Syfovre treatment slowed lesion growth by ~1.5 years vs projected sham — with consistent safety through year 5.
Full story: https://ow.ly/ZOpo50Xuz76
#Ophthalmology #Retina #GA #AMD #ClinicalTrials
A world first: Precise Bio has implanted the first 3D-bio-printed corneal implant (PB-001) in a patient at Rambam Medical Center.
Built from living corneal cells, the implant aims to reduce donor dependence and restore sight.
Full story: https://ow.ly/b0sx50XuyRL
#Ophthalmology
Built from living corneal cells, the implant aims to reduce donor dependence and restore sight.
Full story: https://ow.ly/b0sx50XuyRL
#Ophthalmology
November 21, 2025 at 2:10 PM
A world first: Precise Bio has implanted the first 3D-bio-printed corneal implant (PB-001) in a patient at Rambam Medical Center.
Built from living corneal cells, the implant aims to reduce donor dependence and restore sight.
Full story: https://ow.ly/b0sx50XuyRL
#Ophthalmology
Built from living corneal cells, the implant aims to reduce donor dependence and restore sight.
Full story: https://ow.ly/b0sx50XuyRL
#Ophthalmology
At #AAO2025, ASC leaders shared practical ways to boost efficiency — from precision turnover and smarter tech integration to “all hands on deck” teamwork.
Full insights:
https://ow.ly/9uwx50XuxMF
#Ophthalmology #ASC #SurgeryCenters
Full insights:
https://ow.ly/9uwx50XuxMF
#Ophthalmology #ASC #SurgeryCenters
November 20, 2025 at 2:45 PM
At #AAO2025, ASC leaders shared practical ways to boost efficiency — from precision turnover and smarter tech integration to “all hands on deck” teamwork.
Full insights:
https://ow.ly/9uwx50XuxMF
#Ophthalmology #ASC #SurgeryCenters
Full insights:
https://ow.ly/9uwx50XuxMF
#Ophthalmology #ASC #SurgeryCenters
CAM in oculoplastics: less inflammation and scarring, better handling, and strong outcomes in eyelid and socket reconstruction. When to choose thicker grafts, how to set expectations, and where CAM beats traditional grafts.
Read: https://ow.ly/ELBG50XpVvp
#Ophthalmology
Read: https://ow.ly/ELBG50XpVvp
#Ophthalmology
November 19, 2025 at 2:25 PM
CAM in oculoplastics: less inflammation and scarring, better handling, and strong outcomes in eyelid and socket reconstruction. When to choose thicker grafts, how to set expectations, and where CAM beats traditional grafts.
Read: https://ow.ly/ELBG50XpVvp
#Ophthalmology
Read: https://ow.ly/ELBG50XpVvp
#Ophthalmology
Dry eye is entering a new phase. A Lumenis panel at VisionExpo West highlighted overlooked factors like lower lid laxity and the dominant role of MGD, along with the growing impact of IPL and advanced diagnostics.
Full story:
https://ow.ly/HBuc50XsWEg
#DryEye #MGD #Ophthalmology
Full story:
https://ow.ly/HBuc50XsWEg
#DryEye #MGD #Ophthalmology
November 18, 2025 at 4:20 PM
Dry eye is entering a new phase. A Lumenis panel at VisionExpo West highlighted overlooked factors like lower lid laxity and the dominant role of MGD, along with the growing impact of IPL and advanced diagnostics.
Full story:
https://ow.ly/HBuc50XsWEg
#DryEye #MGD #Ophthalmology
Full story:
https://ow.ly/HBuc50XsWEg
#DryEye #MGD #Ophthalmology
👁️ The Nov/Dec issue of Ophthalmology Management is here!
This issue looks ahead to the future of ophthalmic care — from innovation in presbyopia and pterygium treatments to evolving surgical techniques and smarter practice management.
📖 Explore the full digital edition: https://ow.ly/1Lin50XpVRc
This issue looks ahead to the future of ophthalmic care — from innovation in presbyopia and pterygium treatments to evolving surgical techniques and smarter practice management.
📖 Explore the full digital edition: https://ow.ly/1Lin50XpVRc
November 17, 2025 at 2:35 PM
👁️ The Nov/Dec issue of Ophthalmology Management is here!
This issue looks ahead to the future of ophthalmic care — from innovation in presbyopia and pterygium treatments to evolving surgical techniques and smarter practice management.
📖 Explore the full digital edition: https://ow.ly/1Lin50XpVRc
This issue looks ahead to the future of ophthalmic care — from innovation in presbyopia and pterygium treatments to evolving surgical techniques and smarter practice management.
📖 Explore the full digital edition: https://ow.ly/1Lin50XpVRc
👀 New research provides the first real-time look at how VR use affects tear film dynamics. A built-in micro-camera in a VR headset showed tear film changes and temperature increases during a 30-minute session.
👉 Read more: https://ow.ly/sqkI50XrbOq
#Ophthalmology #VR #EyeHealth
👉 Read more: https://ow.ly/sqkI50XrbOq
#Ophthalmology #VR #EyeHealth
November 14, 2025 at 5:10 PM
👀 New research provides the first real-time look at how VR use affects tear film dynamics. A built-in micro-camera in a VR headset showed tear film changes and temperature increases during a 30-minute session.
👉 Read more: https://ow.ly/sqkI50XrbOq
#Ophthalmology #VR #EyeHealth
👉 Read more: https://ow.ly/sqkI50XrbOq
#Ophthalmology #VR #EyeHealth